Condition: Gastric Cancer · Gastro-esophageal Junction Cancer · Pancreatic Ductal Adenocarcinoma · Sponsor: AstraZeneca
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Jacksonville, Florida, United States | Recruiting |
| Research Site | Rochester, Minnesota, United States | Recruiting |
| Research Site | New York, New York, United States | Withdrawn |
| Research Site | Beijing, China | Recruiting |
| Research Site | Beijing, China | Recruiting |
| Research Site | Shandong, China | Recruiting |
| Research Site | Toulouse, France | Recruiting |
| Research Site | Villejuif, France | Recruiting |
| Research Site | Chūōku, Japan | Recruiting |
| Research Site | Kashiwa, Japan | Recruiting |
| Research Site | Kōtoku, Japan | Recruiting |
| Research Site | Amsterdam, Netherlands | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06005493